Serum creatinine is associated with coronary disease risk even in the absence of metabolic disorders

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 73, Issue 7, 2013, Pages 569-575

  Onat, Altan ^a   Yüksel, Hüsniye ^a   Can, Günay ^a   Köroǧlu, Bayram ^b   Kaya, Ayşem ^c   Altay, Servet ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b DR SIYAMI ERSEK THORACIC AND CARDIOVASCULAR SURGERY TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Apolipoprotein A I; Coronary heart disease risk; Creatinine; Dysfunction of high density lipoproteins; Lipoprotein(a)

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOVASCULAR RISK; CHEMICAL ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING; SYSTOLIC BLOOD PRESSURE; TURKEY (REPUBLIC);

ADULT; AGED; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CORONARY DISEASE; CREATININE; DIABETES MELLITUS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS;

EID: 84884930479     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365513.2013.821712     Document Type: Article

References (28)

1. Grundy S M, Benjamin U, Burke G L, Chait A, Eckel R H, Howard BV, Mitch W, Smith SC Jr, Sowers JR. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999 ; 100 : 1134-46. (Pubitemid 29416243)
2. Grundy S M, Brewer H B, Cleeman J I, Smith S C, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004 ; 109 : 433-8. (Pubitemid 38133916)
3. Fruchart J-C, Sacks F M, Hermans M P, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche JM, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P. Residual Risk Reduction Initiative (R3I). The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diabetes Vasc Dis Res 2008 ; 5 : 319-35.
4. Cornier M-A, Despres J-P, Davis N, Grossniklaus DA, Klein S, Lamarche B, Lopez-Jimenez F, Rao G, St-Onge MP, Towfighi A, Poirier P. on behalf of the American Heart Association Obesity Committee of the Council on Nutrition; Physical Activity and Metabolism; Council on Arteriosclerosis; Thrombosis and Vascular Biology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing, Council on Epidemiology and Prevention; Council on the Kidney in Cardiovascular Disease, and Stroke Council. Assessing adiposity: a Scientific Statement from the American Heart Association. Circulation 2011 ; 124 : 1996 - 2019.
5. De Lorenzo A, Del Gobbo V, Premrov MG, Bigioni M, Galvano F, Di Renzo L. Normal-weight obese syndrome: early inflammation? Am J Clin Nutr 2007 ; 85 : 40-5. (Pubitemid 46067613)
6. Romero-Corral A, Somers VK, Sierra-Johnson J, Korenfeld Y, Boarin S, Korinek J, Jensen MD, Parati G, Lopez-Jimenez F. Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality. Eur Heart J 2010 ; 31 : 737-46.
7. Knight EL, Rimm EB, P ai JK, R exrode KM, Cannuscio CC, Manson JE, Stampfer MJ, Curhan GC. Kidney dysfunction, inflammation, and coronary events: a prospective study. J Am Soc Nephrol 2004 ; 15 : 1897 - 903. (Pubitemid 38822070)
8. Onat A, Hergenc G. Low-grade inflammation and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiometabolic risk. Metabolism 2011 ; 60 : 499-512.
9. Onat A, Hergenc G, Bulur S, Uǧur M, Kücükdurmaz Z, Can G. The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks. Int J Cardiol 2010 ; 142 : 72-9.
10. Onat A, Can G, Ayhan E, Kaya Z, Hergenc G. I mpaired protection against diabetes and coronary disease by highdensity lipoproteins in Turks. Metabolism 2009 ; 58 : 1393-9.
11. Onat A, C an G, A demoglu Ecelik E, Karagöz A, Ornek E. Coronary disease risk curve of serum creatinine is linear in Turkish men, U-shaped in women. J Investig Med 2013 ; 61 :27 - 33.
12. Onat A, C an G. E nhanced pro-inflammatory state and autoimmune activation: a breakthrough to understanding chronic diseases. Curr Pharmaceut Design 2013 Apr 2 [Epub]
13. Wang J, Gong J, Li H, Niu D, Han A, Wu J, Zhang C. Lipoprotein(a) complexes with beta2-glycoprotein I in patients with coronary artery disease. J Atheroscler Thromb 2012 ; 19 : 81-9.
14. Onat A. R isk factors and cardiovascular disease in Turkey. Atherosclerosis 2001 ; 156 : 1-10. (Pubitemid 32429589)
15. Onat A, U yarel H, H ergenc G, K arabulut A, A lbayrak S, Can G. Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. Atherosclerosis 2007 ; 191 : 182 - 90. (Pubitemid 46237629)
16. Genuth S, A lberti KG, B ennett P, B use J, D efronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P ; Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003 ; 26 : 3160-7. (Pubitemid 37339514)
17. Rose GA, B lackburn H, G illum RF, P rineas RJ. C ardiovascular Survey Methods, 2nd edn. Geneva: WHO, 1982, p. 124 - 7.
18. Nelson RG, Bennett PH, Beck GJ, Tan M, Knowler WC, Mitch WE, Hirschman GH, Myers BD. Development and progression of renal disease in Pima Indians with noninsulin- dependent diabetes mellitus. Diabetic Renal Disease Study Group. N Engl J Med 1996 ; 335 : 1636-42. (Pubitemid 26392728)
19. Harita N, Hayashi T, Sato K K, Nakamura Y, Yoneda T, Endo G, Kambe H. Lower serum creatinine is a new risk factor of type 2 diabetes: the Kansai healthcare study. Diabetes Care 2009 ; 32 : 424-6.
20. Tomaszewski M, Charchar F J, Maric C, McClure J, Crawford L, Grzeszczak W, Sattar N, Zukowska- Szczechowska E, Dominiczak AF. Glomerular hyperfiltration: a new marker of metabolic risk. Kidney Int 2007 ; 71 : 816-21. (Pubitemid 46624026)
21. Lorenzo C, Nath SD, Hanley AJG, Abboud HE, Gelfond JA, Haffner SM. Risk of type 2 diabetes among individuals with high and low glomerular filtration rates. Diabetologia 2009 ; 52 : 1290-7.
22. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999 ; 56 : 2214-9. (Pubitemid 30004750)
23. Rule AD, R odeheffer R J, L arson TS, B urnett T S Jr, Cosio FG, Turner ST, Jacobsen ST. Limitation of estimating glomerular filtration rate from serum creatinine in the general population. Mayo Clin Proc 2006 ; 81 : 1427-34. (Pubitemid 44685008)
24. Tsironis LD, Katsouras CS, Lourida ES, Mitsios JV, Goudevenos J, Elisaf M, Tselepis AD. Reduced PAFacetylhydrolase activity associated with Lp(a) in patients with coronary artery disease. Atherosclerosis 2004 ; 177 : 193-201. (Pubitemid 39361156)
25. Farsi A, Domeneghetti MP, Fedi S, Capanni M, Giusti B, Marcucci R, Giurlani L, Prisco D, Passaleva A, Gensini GF, Abbate R. High prevalence of anti-beta 2 glycoprotein I antibodies in patients with ischemic heart disease. Autoimmunity 1999 ; 30 : 93-8. (Pubitemid 29363863)
26. Worgall T S. Sphingolipids: major regulators of lipid metabolism. Curr Opin Clin Nutr Metab Care 2007 ; 10 : 149-55. (Pubitemid 46220306)
27. Ogasawara K, Mashiba S, Hashimoto H, Kojima S, Matsuno S, Takeya M, Uchida K, Yajima J. Low-density lipoprotein (LDL), which includes apolipoprotein A-I (apoAI-LDL) as a novel marker of coronary artery disease. Clin Chim Acta 2008 ; 397 : 42-7.
28. Haase CL, Tybjaerg-Hansen A, Grande P, Frikke-Schmidt R. Genetically elevated apolipoprotein A-I, high-density lipoprotein cholesterol levels, and risk of ischemic heart disease. J Clin Endocrinol Metab 2010 ; 95 : E500 - 10.